Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Organic Chemicals
Clear Filters

Search Clinical Trials

33 Results
Completed
A Trial of Levodopa in Angelman Syndrome
Levodopa is a prodrug that "delivers" dopamine to the brain. It is usually given with carbidopa, a peripheral decarboxylase inhibitor, to increase the bioavailability of levodopa. Animal studies have suggested …
Baylor Role: Collaborator
Completed
Varenicline as a Treatment for Methamphetamine Dependence
This study is part of an effort to develop treatments for methamphetamine abuse. Varenicline is a drug that changes levels of certain brain chemicals that may also be useful in …
Baylor Role: Lead Sponsor
Completed
Modafinil - Escitalopram Study for Cocaine Dependence
In this application, we propose an augmentation strategy intended to improve the efficacy of modafinil as a potential treatment for cocaine dependence. Recent data indicates that during chronic treatment modafinil …
Baylor Role: Lead Sponsor
Completed
NAC as a Potential Treatment for Methamphetamine Dependence
N-acetyl-l-cysteine (NAC) treatment is associated with reduced susceptibility to reinstatement of cocaine seeking behavior in rats (Baker et al 2002) and with reduced cue-induced craving in cocaine-dependent human volunteers (LaRowe …
Baylor Role: Lead Sponsor
Withdrawn
RTI-336 as a Treatment for Methamphetamine Dependence
Methamphetamine (METH) is a highly addictive stimulant and acute exposure causes dopamine (DA) release and stimulates midbrain reward centers. The proposed work represents an important research effort with considerable public …
Baylor Role: Lead Sponsor
Completed
Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans
HYPOTHESES Primary Hypothesis: Compared to placebo treatment, nepicastat-treated OIF/OEF veterans with PTSD will have significantly reduced PTSD hyperarousal symptoms as defined by the Clinician Administered PTSD Scale [CAPS], subscale D …
Baylor Role: Collaborator
Completed
Rivastigmine as a Treatment for Methamphetamine Dependence
We recently completed a double-blind placebo-controlled human laboratory study demonstrating that treatment with a low dose of the acetylcholinesterase (AChE) inhibitor rivastigmine reduced methamphetamine (METH)-induced craving (see Preliminary Studies, Fig. …
Baylor Role: Lead Sponsor
Completed
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
Our preliminary data indicate that the ACE inhibitor perindopril can attenuate MA-induced drug craving, suggesting that perindopril should be evaluated as a treatment for MA dependence. Candesartan works similarly to …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
The donor gave us blood to make CD19 chimeric receptor trivirus specific T cells in the laboratory. These cells were grown and frozen for the subject. To make these special …
Baylor Role: Lead Sponsor
Completed
Pain and Anxiety Management With Oral Narcotic for Pediatric Suture Repair
A prospective, double-blind, placebo-controlled, randomized clinical trial in a tertiary care pediatric emergency department with an annual census of 80,000 visits per year. Patients will be randomized by a randomization …
Baylor Role: Lead Sponsor